• Optimizing Cell Assays with Recombinant Human EGF

  2026-06-23

  Recombinant human EGF, expressed in E. coli, streamlines cell proliferation and mucosal healing workflows with unmatched purity and reproducibility. This article delivers actionable protocols, troubleshooting strategies, and advanced experimental insights that empower researchers to unlock the full potential of EGF in cell culture and oncology.

• CD28-ARS2 Axis Drives PKM Splicing and Metabolic Flexibility

  2026-06-22

  This study reveals that the CD28-ARS2 signaling axis orchestrates alternative splicing of the pyruvate kinase gene (PKM), enabling metabolic flexibility and robust antitumor function in CD8+ T cells. The findings provide mechanistic insight into how T cell activation rewires metabolism beyond canonical signaling pathways, with implications for immunotherapy design.

• Indomethacin in Inflammation Research: Protocols & Innovatio

  2026-06-22

  Indomethacin’s unique Cox-1 selectivity and PPARγ agonism make it a crucial tool for dissecting inflammation, lipid metabolism, and membrane signaling pathways. This article delivers enhanced protocols, troubleshooting insights, and bridges recent mechanistic studies to practical bench workflows, helping researchers maximize reproducibility and experimental clarity.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-06-21

  CX-5461, a potent RNA polymerase I inhibitor, is transforming cancer research by enabling precise modulation of ribosome biogenesis and uncovering new strategies for targeting solid tumor growth and chemoresistance. This article provides actionable workflows, troubleshooting guidance, and contextualizes the latest breakthroughs for advanced users.

• Single-Cell ERK Dynamics Reveal EGFR's Role in Mutant CRC Si

  2026-06-20

  This study utilizes patient-derived colorectal cancer organoids and an advanced FRET-based biosensor to quantify ERK dynamics at the single-cell level. The findings demonstrate that EGFR activity amplifies oncogenic MAPK pathway signaling in KRAS and BRAF mutant tumors, providing mechanistic insight into why combined EGFR and MAPK inhibition is more effective than targeting the pathway alone.

• CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1

  2026-06-19

  This study reveals that Cdc2-like kinase 2 (CLK2) confers platinum resistance in ovarian cancer by phosphorylating BRCA1, enhancing DNA repair and impairing chemotherapeutic efficacy. These mechanistic insights suggest CLK2 as a promising therapeutic target for overcoming resistance in BRCA-associated cancer therapy.

• Hyaluronic Acid Sodium Salt: Unveiling New Mechanisms for Ta

  2026-06-19

  Explore the pivotal role of hyaluronic acid sodium salt in advanced siRNA delivery, extracellular matrix engineering, and immune modulation. This in-depth analysis highlights unique mechanistic insights and practical workflow strategies for researchers utilizing sodium hyaluronate in cutting-edge biomedical applications.

• (-)-JQ1: Gold-Standard Inactive Control in BET Research

  2026-06-18

  (-)-JQ1, the inactive JQ1 stereoisomer, is a rigorously validated negative control for BET bromodomain inhibition studies. Its lack of BRD4 binding enables researchers to distinguish specific from nonspecific effects in epigenetics and cancer biology research.

• Nigericin: Applied Protocols for Ionophore-Driven Cancer Res

  2026-06-18

  Nigericin’s unique potassium/hydrogen ion carrier function is transforming experimental oncology, enabling precise intracellular pH modulation and mitochondrial ion transport studies. This article offers actionable workflows, troubleshooting insights, and a translational bridge to antibiotic potentiation—anchored by recent metabolomic breakthroughs.

• Nuclear-Targeted Peptide Nanorods Amplify STING-Mediated Imm

  2026-06-17

  Wu et al. introduce nuclear-targeted chimeric peptide nanorods that co-deliver a photosensitizer and DMXAA (Vadimezan) to tumor cell nuclei, generating reactive oxygen species for localized DNA damage and robust STING pathway activation. This dual approach enhances innate anti-tumor immunity, providing a strategic advance for immunotherapeutic intervention in metastatic cancer models.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine:

  2026-06-17

  Unlock advanced immune modulation and post-surgical osteosarcoma recurrence research with 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine. This guide provides concrete workflow enhancements, troubleshooting strategies, and actionable protocol parameters for maximizing reproducibility and insight in α2-adrenergic receptor signaling studies.

• Microbiota-Based Modulation of Neuroinflammation in Chronic

  2026-06-16

  This study introduces [18F]PBR146 PET imaging to noninvasively monitor neuroinflammation in a rat model of chronic hepatic encephalopathy (HE), and directly compares the therapeutic potential of Bifidobacterium and fecal microbiota transplantation (FMT). Results reveal that Bifidobacterium, but not FMT, attenuates region-specific neuroinflammation, providing mechanistic insight into gut–liver–brain axis interventions.

• 5-Azacytidine (5-AzaC): Mechanism, Benchmarks & Protocols

  2026-06-16

  5-Azacytidine (5-AzaC) is a cytosine analogue and potent DNA methyltransferase inhibitor, widely used in epigenetic and cancer research. APExBIO’s A1907-grade 5-Azacytidine offers validated demethylation, gene reactivation, and cytotoxic benchmarks in leukemia and multiple myeloma models. This article details its mechanism, evidence, and workflow integration with direct protocol and troubleshooting advice.

• Ginsenoside Rg1 Restores Neuroimmune Balance After Anesthesi

  2026-06-15

  The reference study demonstrates that Ginsenoside Rg1, a triterpene saponin from Panax ginseng, reverses gut-immune-brain axis disruptions and cognitive deficits induced by prolonged isoflurane anesthesia in mice. Regulatory T cells were shown to mediate these neuroprotective effects, offering mechanistic insight for developing targeted interventions against anesthesia-related neuroimmune dysfunction.

• BMX Kinase Regulates Lysosomal Acidification in Mtb Infectio

  2026-06-15

  This study uncovers how Mycobacterium tuberculosis manipulates host cell lysosomal acidification by modulating BMX kinase-mediated phosphorylation of the V-ATPase E1 subunit, facilitating its own intracellular survival. The findings highlight BMX kinase as a critical regulator of phagosome maturation and suggest that targeting BMX could advance host-directed therapies for tuberculosis.

456 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page